Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Safia ChaturMuthiah VaduganathanBrian ClaggettOrly VardenyAkshay S DesaiPardeep S JhundRudolf A de BoerCarolyn S P LamMikhail N KosiborodSanjiv J ShahFelipe MartinezSilvio E InzucchiAdrian F HernandezTariq HaddadSumeet S MitterZi Michael MiaoMagnus PeterssonAnna Maria LangkildeJohn J V McMurrayScott D SolomonPublished in: European heart journal (2023)
In patients with heart failure with mildly reduced or preserved ejection fraction, the clinical benefits of dapagliflozin relative to placebo were consistent across a wide range of diuretic categories and doses with a similar safety profile. Treatment with dapagliflozin significantly reduced new loop diuretic requirement over time.